Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry.
about
Cancer cells with irons in the fireMethodological problems with population cancer studies: The forgotten confounding factors.Myelodysplastic Syndromes and Iron Chelation TherapyDeferasirox in a refractory anemia after other treatment options: case report and literature review.The risk of infections in patients with myelodysplastic syndromes in 2016.Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.Emerging biological therapies for the treatment of myelodysplastic syndromes.Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.Iron chelation therapy in low risk myelodysplastic syndrome.Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehydrogenase.Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome.Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromesOverall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
P2860
Q26851312-F4C0B5C8-66E6-4709-AA96-A1FC0A44C09EQ35681923-3E8127D9-EB81-4E5E-9251-326C3FAE69B5Q37677229-F4C9A38C-18EC-4521-B811-32F776BF7106Q38549248-48BE2A56-C24B-48CE-A978-5F783AB5F54EQ38813702-C0414A22-E4F6-487E-8185-6B6F7161ECE6Q38832241-A91968A5-A9D1-4B27-B574-B12917AA86C6Q38834981-3F7315DC-3D4D-48F9-8A7C-83D8EF4C8D78Q38838933-FE3FF52D-97DB-4754-B173-D67FF82BEA10Q38903926-39570A9F-940F-400D-B7FA-1B4DB6EFFEECQ40387078-69944CA6-1762-429B-A3BA-B0AEBBD5B029Q40800759-5506A729-9444-4949-A302-C3D8BB859F9FQ41323380-9CF50A72-6B89-45B4-AD3D-46439C9498ADQ41856578-443E81F5-BB17-4B02-A3EB-E22E85859E84Q48175966-EFC169B2-506E-45B7-AF82-1233EE770840Q50455137-780CAD23-A3E6-4DFA-9590-7890D0C420F5
P2860
Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Comparison of 24-month outcome ...... mes in a prospective registry.
@en
Comparison of 24-month outcome ...... mes in a prospective registry.
@nl
type
label
Comparison of 24-month outcome ...... mes in a prospective registry.
@en
Comparison of 24-month outcome ...... mes in a prospective registry.
@nl
prefLabel
Comparison of 24-month outcome ...... mes in a prospective registry.
@en
Comparison of 24-month outcome ...... mes in a prospective registry.
@nl
P2093
P1433
P1476
Comparison of 24-month outcome ...... mes in a prospective registry.
@en
P2093
Billie J Marek
Carole Paley
Jason Esposito
Lawrence Garbo
Nicholas DiBella
Roger M Lyons
P304
P356
10.1016/J.LEUKRES.2013.11.004
P577
2013-11-13T00:00:00Z